MSB 2.17% $1.13 mesoblast limited

Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-5

  1. 12,429 Posts.
    lightbulb Created with Sketch. 3371
    There you go... the reason for the Ryoncil BLA Resubmission delay

    They were waiting for this - I feel better now biggrin.png

    I'll see you guys at the AGM - I'll be in a blue top, so come over and say hi if you are in the room!


    Key Points:
    • Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3trial MSB-GVHD001
    • Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recentlypublished studies of children or adults with SR-aGVHD who received best available therapy(BAT) or the only approved agent in adults1-4
    • These results reaffirm the potential significance of remestemcel-L as a life-saving therapy forchildren with SR-aGVHD
    • These long-term survival outcomes are a key component of the Biologics License Application(BLA) resubmission to the United States Food and Drug Administration (FDA)
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13
Change
-0.025(2.17%)
Mkt cap ! $1.284B
Open High Low Value Volume
$1.15 $1.16 $1.11 $7.363M 6.488M

Buyers (Bids)

No. Vol. Price($)
5 94863 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.13 5000 2
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.